|
186 Companies |
|
244 Products |
|
244 Products |
|
91 Mechanisms of Action |
|
17 Trials |
|
2576 News |
|
| «12...56789101112131415...5253» |
- cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial primary completion date, Post-transplantation: Combination Chemotherapy, Bone Marrow Transplant, and Post Transplant Cyclophosphamide for Hematologic Cancer (clinicaltrials.gov) - Oct 18, 2016
P2, N=92, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Jan 2015 --> Apr 2017
- || dasatinib / Generic mfg.
Trial primary completion date, Pleural effusion: PASS: Frequency and Severity of Pleural Effusion Associated With the Use of Dasatinib in Patients With Chronic Myeloid Leukemia. A Descriptive, Mexican Multicenter Study (clinicaltrials.gov) - Oct 18, 2016
P=N/A, N=100, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Jan 2015 --> Apr 2017 Trial primary completion date: Aug 2016 --> Mar 2017
- lenalidomide / Generic mfg.
Trial primary completion date: Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia (clinicaltrials.gov) - Oct 17, 2016
P2, N=48, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Aug 2016 --> Mar 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- Trial primary completion date: Bone Marrow Transplant Trial for Patients With Refractory Severe Aplastic Anemia (clinicaltrials.gov) - Oct 13, 2016
P2, N=4, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Jun 2015 --> Aug 2014
- | clofarabine / Generic mfg.
Enrollment closed, Trial primary completion date: Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML) (clinicaltrials.gov) - Oct 13, 2016
P1/2, N=20, Active, not recruiting, Sponsor: University Hospital Southampton NHS Foundation Trust.
Trial primary completion date: Jun 2015 --> Aug 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> May 2014
- Trial primary completion date, IO biomarker: A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome (clinicaltrials.gov) - Oct 12, 2016
P1/2, N=40, Recruiting, Sponsor: Opsona Therapeutics Ltd.
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2016 --> May 2014 Trial primary completion date: May 2016 --> Jun 2018
- | Promacta (eltrombopag) / Novartis
New P2 trial, Combination therapy: Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q (clinicaltrials.gov) - Oct 11, 2016
P2, N=144, Recruiting, Sponsor: Associazione Qol-one
- imatinib / Generic mfg.
Trial completion: Glivec in Pediatric Chronic Myeloid Leukemia (CML) (clinicaltrials.gov) - Oct 11, 2016
P4, N=44, Completed, Sponsor: Poitiers University Hospital
Trial primary completion date: May 2016 --> Jun 2018 Active, not recruiting --> Completed
- zoledronic acid / Generic mfg.
Trial primary completion date, Metastases: Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement (clinicaltrials.gov) - Oct 11, 2016
P3, N=1758, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Trial primary completion date: May 2015 --> Jun 2014
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
Trial termination, Trial primary completion date: T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant (clinicaltrials.gov) - Oct 11, 2016
P2, N=34, Terminated, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: May 2015 --> Jun 2014 Recruiting --> Terminated | Trial primary completion date: Aug 2018 --> Dec 2015; Study was terminated in August 2016 due to replacement by a new study.
- ||||| GSK2879552 / GSK
New P2 trial, Combination therapy: Safety, Clinical Activity, Pharmacokinetics (PK) and Pharmacodynamics Study of GSK2879552, Alone or With Azacitidine, in Subjects With High Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Oct 11, 2016
P2, N=74, Not yet recruiting, Sponsor: GlaxoSmithKline
- arsenic trioxide / Generic mfg.
Enrollment change, Trial withdrawal: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov) - Oct 5, 2016
P2, N=0, Withdrawn, Sponsor: Stanford University
Recruiting --> Terminated | Trial primary completion date: Aug 2018 --> Dec 2015; Study was terminated in August 2016 due to replacement by a new study. N=16 --> 0 | Not yet recruiting --> Withdrawn
- busulfan / Generic mfg., clofarabine / Generic mfg.
Trial completion: Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation (clinicaltrials.gov) - Oct 4, 2016
P2, N=34, Completed, Sponsor: Massachusetts General Hospital
N=16 --> 0 | Not yet recruiting --> Withdrawn Active, not recruiting --> Completed
- Zyflo (zileuton) / Chiesi
Enrollment change, Trial termination, Combination therapy: Evaluating the Safety of Zileuton (Zyflo (clinicaltrials.gov) - Sep 30, 2016
P1, N=2, Terminated, Sponsor: University of Massachusetts, Worcester
Active, not recruiting --> Completed N=18 --> 2 | Recruiting --> Terminated; Low accrual
- Enrollment closed, Enrollment change, Trial primary completion date: Multicenter Study of Magnetic Resonance-guided High Intensity Focused Ultrasound for Pain Palliation of Bone Metastases (clinicaltrials.gov) - Sep 28, 2016
P=N/A, N=20, Active, not recruiting, Sponsor: Philips Healthcare
N=18 --> 2 | Recruiting --> Terminated; Low accrual Recruiting --> Active, not recruiting | N=64 --> 20 | Trial primary completion date: Sep 2017 --> Sep 2016
- sirolimus / Generic mfg.
Enrollment closed, Enrollment change, Immune cell: Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers (clinicaltrials.gov) - Sep 26, 2016
P2, N=377, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=64 --> 20 | Trial primary completion date: Sep 2017 --> Sep 2016 Recruiting --> Active, not recruiting | N=510 --> 377
- New trial: PEG-MF: Interferon-pegyle α2a Efficiency and Tolerance in Myelofibrosis (clinicaltrials.gov) - Sep 22, 2016
P=N/A, N=100, Recruiting, Sponsor: University Hospital, Brest
- | Enrollment open, Trial initiation date, Trial primary completion date: EXPHAR: A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. (clinicaltrials.gov) - Sep 22, 2016
P4, N=20, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=510 --> 377 Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> May 2016 | Trial primary completion date: Apr 2017 --> Nov 2017
- Trial completion, Enrollment change, Trial primary completion date: High-Tc Susceptometer to Monitor Transfusional Iron Overload (clinicaltrials.gov) - Sep 21, 2016
P2, N=99, Completed, Sponsor: Columbia University
Not yet recruiting --> Recruiting | Initiation date: Jan 2016 --> May 2016 | Trial primary completion date: Apr 2017 --> Nov 2017 Recruiting --> Completed | N=190 --> 99 | Trial primary completion date: Aug 2016 --> Oct 2015
- fludarabine IV / Generic mfg., busulfan / Generic mfg.
Trial completion, Trial primary completion date: Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer (clinicaltrials.gov) - Sep 21, 2016
P1/2, N=204, Completed, Sponsor: OHSU Knight Cancer Institute
Recruiting --> Completed | N=190 --> 99 | Trial primary completion date: Aug 2016 --> Oct 2015 Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Aug 2015
- Epogen (epoetin alfa) / Amgen
Enrollment change: A Phase 2 Study to Evaluate the Safety and Effectiveness of Once Weekly or Once Every Two Week Dosing of Epoetin Alfa in Anemic Patients With Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) (clinicaltrials.gov) - Sep 20, 2016
P2, N=0, Withdrawn, Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Active, not recruiting --> Completed | Trial primary completion date: Mar 2015 --> Aug 2015 N=100 --> 0
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Trial completion: RAEB-t: Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Sep 20, 2016
P3, N=600, Completed, Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
N=100 --> 0 Active, not recruiting --> Completed
- Tasigna (nilotinib) / Novartis, Inhibikase
Trial initiation date, Trial primary completion date: Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia (clinicaltrials.gov) - Sep 20, 2016
P2, N=100, Not yet recruiting, Sponsor: Emory University
Active, not recruiting --> Completed Initiation date: Dec 2016 --> Mar 2017 | Trial primary completion date: Dec 2019 --> Mar 2020
- Privigen (human immune globulin intravenous 10%) / CSL Behring
Enrollment change, Trial termination, Trial primary completion date: A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy (clinicaltrials.gov) - Sep 16, 2016
P4, N=17, Terminated, Sponsor: David M. Simpson
Initiation date: Dec 2016 --> Mar 2017 | Trial primary completion date: Dec 2019 --> Mar 2020 N=30 --> 17 | Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Sep 2016; Difficulty with enrollment
- Trial completion, Trial primary completion date, Patient reported outcomes: Patient Reported Outcomes in Chronic Myeloid Leukemia (clinicaltrials.gov) - Sep 15, 2016
P=N/A, N=480, Completed, Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto
N=30 --> 17 | Recruiting --> Terminated | Trial primary completion date: Jun 2016 --> Sep 2016; Difficulty with enrollment Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Sep 2013
- Jakafi (ruxolitinib) / Incyte
Enrollment change, Trial withdrawal, Trial primary completion date: Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis (clinicaltrials.gov) - Sep 14, 2016
P1, N=0, Withdrawn, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed | Trial primary completion date: Sep 2015 --> Sep 2013 N=30 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Nov 2018 --> Sep 2016
- Trial completion, Trial primary completion date: Fertility Preservation in Women Who Will Have Gonadotoxic Therapy or Hematopoetic Stem Cell Transplantation, and in Women With Sickle Cell Disease (clinicaltrials.gov) - Sep 13, 2016
P=N/A, N=10, Completed, Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
N=30 --> 0 | Active, not recruiting --> Withdrawn | Trial primary completion date: Nov 2018 --> Sep 2016 Suspended --> Completed | Trial primary completion date: Aug 2019 --> Sep 2016
- CYAD-01 / Celdara Medical, Celyad Oncology
Enrollment closed, Enrollment change, Metastases: Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands (clinicaltrials.gov) - Sep 12, 2016
P1, N=12, Active, not recruiting, Sponsor: Celdara Medical, LLC
Suspended --> Completed | Trial primary completion date: Aug 2019 --> Sep 2016 Recruiting --> Active, not recruiting | N=21 --> 12
- | imatinib / Generic mfg.
New P2 trial: A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level in Patients Newly Diagnosed With CP-CML (clinicaltrials.gov) - Sep 12, 2016
P2, N=139, Active, not recruiting, Sponsor: Versailles Hospital
- New trial, Adherence: Preparatory Work to Assess Adherence to Oral Chemotherapy (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=120, Not yet recruiting, Sponsor: Wake Forest NCORP Research Base
- New trial, Adverse events: OUEST: Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=286, Completed, Sponsor: University Hospital, Brest
- Elzonris (tagraxofusp) / Menarini, Nippon Shinyaku
Enrollment closed, Trial primary completion date: DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes (clinicaltrials.gov) - Sep 7, 2016
P1/2, N=10, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Active, not recruiting | N=21 --> 12 Completed --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Oct 2018
- imatinib / Generic mfg.
Trial termination: Population Pharmacokinetics of Imatinib in CML Patients in Iran (clinicaltrials.gov) - Sep 7, 2016
P=N/A, N=170, Terminated, Sponsor: Kerman University of Medical Sciences
Completed --> Active, not recruiting | Trial primary completion date: Oct 2014 --> Oct 2018 Enrolling by invitation --> Terminated
- || volasertib (NBL-001) / Oncoheroes, Notable Labs
Trial primary completion date, Combination therapy, Monotherapy: Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes (clinicaltrials.gov) - Sep 7, 2016
P1, N=70, Recruiting, Sponsor: Boehringer Ingelheim
Enrolling by invitation --> Terminated Trial primary completion date: Oct 2017 --> Mar 2018
- imatinib / Generic mfg., pioglitazone / Generic mfg.
New P2 trial: ACTIM: Pioglityazone and Imatinib for CML Patients (clinicaltrials.gov) - Sep 6, 2016
P2, N=27, Completed, Sponsor: Central Hospital, Versailles
- metformin / Generic mfg., cytarabine / Generic mfg.
Trial primary completion date: Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML (clinicaltrials.gov) - Sep 2, 2016
P1, N=2, Active, not recruiting, Sponsor: Northwestern University
Trial primary completion date: Oct 2017 --> Mar 2018 Trial primary completion date: Jul 2016 --> Jul 2018
- | Erivedge (vismodegib) / Roche
Enrollment change, Combination therapy: A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF) (clinicaltrials.gov) - Sep 2, 2016
P1/2, N=20, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Jul 2016 --> Jul 2018 N=94 --> 20
- Enrollment closed: MR-HIFU for Bone Metastases (clinicaltrials.gov) - Aug 31, 2016
P=N/A, N=12, Active, not recruiting, Sponsor: Institute of Cancer Research, United Kingdom
N=94 --> 20 Recruiting --> Active, not recruiting
- | Tasigna (nilotinib) / Novartis, Inhibikase
Trial termination, Trial primary completion date: NISRI: Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy (clinicaltrials.gov) - Aug 31, 2016
P4, N=98, Terminated, Sponsor: King Abdullah International Medical Research Center
Recruiting --> Active, not recruiting Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Aug 2016; Because of many unseen obstacles resulted in poor accrual, study is terminated.
- cytarabine / Generic mfg., decitabine / Generic mfg.
Enrollment closed, Enrollment change, Metastases: Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm (clinicaltrials.gov) - Aug 31, 2016
P=N/A, N=12, Active, not recruiting, Sponsor: University of Washington
Recruiting --> Terminated | Trial primary completion date: Mar 2017 --> Aug 2016; Because of many unseen obstacles resulted in poor accrual, study is terminated. Recruiting --> Active, not recruiting | N=30 --> 12
- ||| Loargys (pegzilarginase) / Immedica
Enrollment open: A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS (clinicaltrials.gov) - Aug 29, 2016
P1, N=58, Recruiting, Sponsor: Aeglea Biotherapeutics
Recruiting --> Active, not recruiting | N=30 --> 12 Not yet recruiting --> Recruiting
- Jakafi (ruxolitinib) / Novartis, Incyte
Trial primary completion date: Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis (clinicaltrials.gov) - Aug 26, 2016
P2, N=28, Active, not recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2016 --> Mar 2017
- | Apocept (asunercept) / Apogenix
Trial completion: APG101 in Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 24, 2016
P1, N=20, Completed, Sponsor: Apogenix GmbH
Trial primary completion date: Dec 2016 --> Mar 2017 Active, not recruiting --> Completed
- New trial: Comparison of NaF PET-CT and Diffusion MRI in the Diagnosis of Bone Metastases (IMMETAOS) (clinicaltrials.gov) - Aug 23, 2016
P=N/A, N=13, Completed, Sponsor: Institut Jean-Godinot
- Thymoglobulin (anti-thymocyte globulin (rabbit)) / Sanofi
New P2 trial: Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients (clinicaltrials.gov) - Aug 23, 2016
P2, N=38, Not yet recruiting, Sponsor: Emory University
- New trial: EVITA-Pilot: Epigenetics, Vitamin C and Abnormal Hematopoiesis - Pilot Study (clinicaltrials.gov) - Aug 23, 2016
P=N/A, N=20, Recruiting, Sponsor: Rigshospitalet, Denmark
- New trial: HSP-SMP: Efficacy of Heat-shock Protein (HSP) Inhibitors in Myeloproliferative Syndromes (MPS) (clinicaltrials.gov) - Aug 21, 2016
P=N/A, N=37, Completed, Sponsor: Centre Hospitalier Universitaire Dijon
- ||| Enrollment open: A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (? 65 Years) With Haematologic Neoplasms (clinicaltrials.gov) - Aug 20, 2016
P=N/A, N=80, Recruiting, Sponsor: Celgene Corporation
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- fludarabine IV / Generic mfg., cyclophosphamide / Generic mfg., busulfan / Generic mfg.
Trial primary completion date: Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine (clinicaltrials.gov) - Aug 16, 2016
P2, N=45, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2016 --> Sep 2017
- Farydak (panobinostat) / Secura Bio
Phase classification, Combination therapy: Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Aug 16, 2016
P1, N=36, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Sep 2016 --> Sep 2017 Phase classification: P1/2 --> P1